 |
|
|
| |
The NS5A Inhibitor GS-5885 Is Safe and Well Tolerated in More Than 1000 Patients Treated in Phase 2 Studies
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Gregory Everson1, Eric Lawitz2, Alex Thompson3, Mark Sulkowski4, Yanni Zhu5, Diana Brainard5, Laura Mendelson5, John McHutchison5, Phil S. Pang5, Jenny C. Yang5, Patrick Marcellin6, Nezam Afdhal7 1University of Colorado Denver, Aurora, CO, United States; 2Alamo Medical Research, San Antonio, TX , United States; 3St. Vincent's Hospital, Melbourne, Australia; 4Johns Hopkins University School of Medicine, Baltimore, MD , United States; 5Gilead Sciences, Inc., Foster City, CA, United States; 6Université Paris-Diderot, Hopital Beaujon, Clichy, France; 7Beth Israel Deaconess Medical Center, Boston, MA , United States
|
| |
|
|
|
|
|
